Nox2 Is a Mediator of Ischemia Reperfusion Injury von Karim, A. S., Reese, S. R., Wilson, N. A., Jacobson, L. M., Zhong, W., Djamali, A.

Volltext

Multistate Outbreak of Fusarium Keratitis Associated With Use of a Contact Lens Solution von Chang, Douglas C, Grant, Gavin B, O’Donnell, Kerry, Wannemuehler, Kathleen A, Noble-Wang, Judith, Rao, Carol Y, Jacobson, Lara M, Crowell, Claudia S, Sneed, Rodlescia S, Lewis, Felicia M. T, Schaffzin, Joshua K, Kainer, Marion A, Genese, Carol A, Alfonso, Eduardo C, Jones, Dan B, Srinivasan, Arjun, Fridkin, Scott K, Park, Benjamin J, Fusarium Keratitis Investigation Team, for the

Volltext

Characterization of Transfusion‐Elicited Acute Antibody‐Mediated Rejection in a Rat Model of Kidney Transplantation von Huang, G., Wilson, N. A., Reese, S. R., Jacobson, L. M., Zhong, W., Djamali, A.

Volltext

Zwittermicin A-producing strains of Bacillus cereus from diverse soils von STABB, E. V, JACOBSON, L. M, HANDELSMAN, J

Volltext

Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution von Chang, D.C., Grant, G.B., O’Donnell, K., Wannemuehler, K.A., Noble-Wang, J., Rao, C.Y., Jacobson, L.M., Crowell, C.S., Sneed, R.S., Lewil, F.M.T., Schaffzin, J.K., Kainer, M.A., Genese, C.A., Alfonso, E.C., Jones, D.B., Srinivasan, A., Fridkin, S.K., Park, B.J.

Volltext

Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes von Brown, Sue A, Kovatchev, Boris P, Raghinaru, Dan, Lum, John W, Buckingham, Bruce A, Kudva, Yogish C, Laffel, Lori M, Levy, Carol J, Pinsker, Jordan E, Wadwa, R. Paul, Dassau, Eyal, Doyle, Francis J, Anderson, Stacey M, Church, Mei Mei, Dadlani, Vikash, Ekhlaspour, Laya, Forlenza, Gregory P, Isganaitis, Elvira, Lam, David W, Kollman, Craig, Beck, Roy W

Volltext

Do cancer survivors who report infertility meet their reproductive goals? von Howards, P.P, Jacobson, M.H, Fothergill, A, Shandley, L.M, Spencer, J, Mertens, A

Volltext

Cancer survivors are at increased risk for early menopause and decreased antral follicle count: results from the FUCHSIA women’s study von Howards, P.P, Jacobson, M.H, Fothergill, A, Chin, H.B, Mertens, A, Shandley, L.M, Spencer, J

Volltext

SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy von Grebely, J, Jacobson, I.M, Kayali, Z, Verna, E.C, Shiffman, M.L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, McHutchison, J.G, Pol, S, Chung, R.T, Bernstein, D.E, Dore, G

Volltext

No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies von Wyles, D, Thompson, A, Lawitz, E, Willems, B, Gane, E.J, Svarovskaia, E, Dvory-Sobol, H, Martin, R, Camus, G, Doehle, B.P, Stamm, L.M, Hyland, R.H, Brainard, D.M, Mo, H.M, Asselah, T, Jacobson, I, Foster, G.R, Roberts, S

Volltext

Acquired Resistance to KRASG12C Inhibition in Cancer von Awad, Mark M, Liu, Shengwu, Rybkin, Igor I, Arbour, Kathryn C, Dilly, Julien, Zhu, Viola W, Johnson, Melissa L, Heist, Rebecca S, Patil, Tejas, Riely, Gregory J, Jacobson, Joseph O, Yang, Xiaoping, Persky, Nicole S, Root, David E, Lowder, Kristen E, Feng, Hanrong, Zhang, Shannon S, Haigis, Kevin M, Hung, Yin P, Sholl, Lynette M, Wolpin, Brian M, Wiese, Julie, Christiansen, Jason, Lee, Jessica, Schrock, Alexa B, Lim, Lee P, Garg, Kavita, Li, Mark, Engstrom, Lars D, Waters, Laura, Lawson, J. David, Olson, Peter, Lito, Piro, Ou, Sai-Hong I, Christensen, James G, Jänne, Pasi A, Aguirre, Andrew J

Volltext

Host factors are associated with vaginal microbiome structure in pregnancy in the ECHO Cohort Consortium von McKee, Kimberly, Bassis, Christine M., Golob, Jonathan, Palazzolo, Beatrice, Sen, Ananda, Comstock, Sarah S., Rosas-Salazar, Christian, Stanford, Joseph B., O’Connor, Thomas, Gern, James E., Paneth, Nigel, Dunlop, Anne L.

Volltext

The safety and tolerability of SOF/VEL/VOX for 8 or 12 weeks in >1,000 patients treated in the POLARIS-1, POLARIS-2, POLARIS-3, and POLARIS-4 studies: an integrated analysis von Manns, M, Gane, E.J, Willems, B.E, Roberts, S.K, Flamm, S, Bourliére, M, Asselah, T, Alric, L, Hyland, R.H, Stamm, L.M, Huang, K.C, Brainard, D.M, Khalili, M, Foster, G.R, Gordon, S.C, Reddy, K.R, Zeuzem, S, Jacobson, I.M, Cooper, C.L, Thompson, A.J, Kowdley, K, Lawitz, E

Volltext

SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 Weeks in DAA-naïve patients: an integrated analysis of the POLARIS-1, PO... von Roberts, S.K, Cooper, C.L, Lawitz, E, Reddy, K.R, Thompson, A.J, Zeuzem, S, Jacobson, I.M, Ruane, P, Hyland, R.H, Stamm, L.M, Han, L, Brainard, D.M, Bräu, N, Asselah, T, Willems, B.E, Flamm, S, Bourlière, M, Foster, G.R, Gane, E.J, Manns, M, Gordon, S.C, Kowdley, K

Volltext

Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor von JACOBSON, Nasreen, ANDREWS, Michael, ALWARD, W. L. M, STONE, Edwin M, CLARK, Abbot F, SHEFFIELD, Val C, SHEPARD, Allan R, NISHIMURA, Darryl, SEARBY, Charles, FINGERT, John H, HAGEMAN, Greg, MULLINS, Robert, DAVIDSON, Beverly L, KWON, Young H

Volltext

High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting... von Lawitz, E, Kowdley, K, Curry, M, Reau, N, Nguyen, M, Kwo, P, Jacobson, I, Tran, T.T, Nahass, R, Hinestrosa, F, Herring, R, Bennet, M, Yang, J.C, Stamm, L.M, An, Di, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Schiff, E, Davis, M, Etzkorn, K, Chung, R.T, Pound, D, Rodriguez-Torres, M, Reddy, K.R, Younes, Z, Gane, E.J

Volltext

Short Duration Treatment with Sofosbuvir/Velpatasvir plus GS-9857 in Treatment-Naive Genotype 1-6 HCV-Infected Patients with or without Cirrhosis von Gane, E.J, Nguyen, M, Kwo, P, Kowdley, K, Reau, N, Jacobson, I, Curry, M, Pearlman, B, Khalid, O, Everson, G, Gordon, S, Poulos, J, Sheikh, A, Bernstein, D, Yang, J.C, Stamm, L.M, An, D, Dvory-Sobol, H, Brainard, D.M, McHutchison, J.G, Tong, M, Tsai, N, Beavers, K.L, Rabinovitz, M, Shiffman, M, Stedman, C, Lawitz, E

Volltext

FRI-235 - SOF/VEL/VOX for 8 or 12 weeks is well tolerated and results in high SVR12 rates in patients receiving opioid substitution therapy von Grebely, J., Jacobson, I.M., Kayali, Z., Verna, E.C., Shiffman, M.L., Hyland, R.H., Stamm, L.M., Huang, K.C., Brainard, D.M., McHutchison, J.G., Pol, S., Chung, R.T., Bernstein, D.E., Dore, G.

Volltext

The Crohn’s disease-associated polymorphism in ATG16L1 (rs2241880) reduces SHIP gene expression and activity in human subjects von Ngoh, E N, Brugger, H K, Monajemi, M, Menzies, S C, Hirschfeld, A F, Del Bel, K L, Jacobson, K, Lavoie, P M, Turvey, S E, Sly, L M

Volltext

THU-257 - No impact of RASs on the high efficacy of SOF/VEL/VOX for 8 weeks in DAA-naïve patients: an integrated resistance analysis of the POLARIS-2 and POLARIS-3 studies von Wyles, D., Thompson, A., Lawitz, E., Willems, B., Gane, E.J., Svarovskaia, E., Dvory-Sobol, H., Martin, R., Camus, G., Doehle, B.P., Stamm, L.M., Hyland, R.H., Brainard, D.M., Mo, H.M., Asselah, T., Jacobson, I., Foster, G.R., Roberts, S.

Volltext